Erwin Surmann
Overview
Explore the profile of Erwin Surmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Y, Tomlinson B, Guo J, Asgharnejad M, Bauer L, Surmann E, et al.
Clin Ther
. 2018 Aug;
40(7):1108-1121.e8.
PMID: 30098648
Purpose: The pharmacokinetic (PK) profile of the rotigotine transdermal patch is well characterized in Caucasian patients with Parkinson's disease (PD) but not in Chinese subjects. This article reports the PK...
2.
Zhang Z, Liu C, Tao E, Shao M, Liu Y, Wang J, et al.
Parkinsonism Relat Disord
. 2017 Aug;
44:6-12.
PMID: 28827011
Introduction: Rotigotine was demonstrated to be efficacious and well-tolerated in three placebo-controlled studies (CLEOPATRA-PD/PREFER/SP921) of patients with advanced-stage Parkinson's disease (PD), most of whom were Caucasian. This multicenter phase 3...
3.
Zhang Z, Shang H, Hu X, Chen S, Zhao Z, Du X, et al.
Parkinsonism Relat Disord
. 2017 Mar;
38:108.
PMID: 28258926
No abstract available.
4.
Hauser R, Slawek J, Barone P, Dohin E, Surmann E, Asgharnejad M, et al.
BMC Neurol
. 2016 Jun;
16:90.
PMID: 27267880
Background: This multicenter, double-blind, placebo-controlled study assessed the efficacy of rotigotine transdermal patch on apathy and motor symptoms in patients with Parkinson's disease (PD). Methods: Patients with PD-associated apathy (Unified...
5.
Zhang Z, Shang H, Hu X, Chen S, Zhao Z, Du X, et al.
Parkinsonism Relat Disord
. 2016 May;
28:49-55.
PMID: 27172830
Introduction: Two phase3 studies (SP512; SP513) involving mostly Caucasian patients showed that rotigotine (≤8 mg/24 h) was efficacious and welltolerated in early-stage Parkinson's disease (PD). We report results from a...
6.
Rascol O, Zesiewicz T, Chaudhuri K, Asgharnejad M, Surmann E, Dohin E, et al.
J Clin Pharmacol
. 2015 Dec;
56(7):852-61.
PMID: 26626320
Pain is a troublesome nonmotor symptom of Parkinson's disease (PD). This double-blind exploratory pilot study (NCT01744496) was the first to specifically investigate the effect of a dopamine agonist on PD-associated...
7.
Giladi N, Ghys L, Surmann E, Boroojerdi B, Jankovic J
Parkinsonism Relat Disord
. 2014 Dec;
20(12):1345-51.
PMID: 25444083
Purpose: In two 6-month, double-blind, placebo-controlled studies, rotigotine transdermal system was well-tolerated and efficacious monotherapy in early-stage PD. This post hoc analysis of the long-term open-label extensions (NCT00594165; NCT00599196) of...
8.
Nicholas A, Borgohain R, Chana P, Surmann E, Thompson E, Bauer L, et al.
J Parkinsons Dis
. 2014 Mar;
4(3):361-73.
PMID: 24643203
Background: Previous phase III studies in patients with advanced Parkinson's disease (PD) not adequately controlled on levodopa demonstrated significant reduction of 'off' time with rotigotine transdermal system up to 16...
9.
Kassubek J, Chaudhuri K, Zesiewicz T, Surmann E, Boroojerdi B, Moran K, et al.
BMC Neurol
. 2014 Mar;
14:42.
PMID: 24602411
Background: Pain is a troublesome non-motor symptom of Parkinson's disease (PD). The RECOVER (Randomized Evaluation of the 24-hour Coverage: Efficacy of Rotigotine; Clintrials.gov: NCT00474058) study demonstrated significant improvements in early-morning...
10.
Swick T, Friedman J, Chaudhuri K, Surmann E, Boroojerdi B, Moran K, et al.
Eur Neurol
. 2014 Jan;
71(3-4):140-7.
PMID: 24457253
Background: RECOVER (NCT00474058), a double-blind, placebo-controlled trial in patients with Parkinson's disease (PD) and unsatisfactory early-morning motor symptom control, demonstrated significant improvements with rotigotine in early-morning motor function (Unified Parkinson's...